Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Irinotecan-Refractory Stage IV Colorectal Cancer
NCT00020930Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2001
- Primary completion
- Aug 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate. Started Mar 2001; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00020930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020930.